Duraphat Tanndreifa 22,6 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

duraphat tanndreifa 22,6 mg/ml

colgate palmolive a/s - natrii fluoridum - tanndreifa - 22,6 mg/ml

Rosuvastatin Xiromed Filmuhúðuð tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rosuvastatin xiromed filmuhúðuð tafla 20 mg

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg

Rosuvastatin Xiromed Filmuhúðuð tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rosuvastatin xiromed filmuhúðuð tafla 10 mg

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

Rosuvastatin Xiromed Filmuhúðuð tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rosuvastatin xiromed filmuhúðuð tafla 5 mg

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

Rosuvastatin Xiromed Filmuhúðuð tafla 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rosuvastatin xiromed filmuhúðuð tafla 40 mg

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Mozobil Evrópusambandið - íslenska - EMA (European Medicines Agency)

mozobil

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - Ónæmisörvandi, - mozobil er ætlað ásamt komfrumu-nýlendunni-örvandi þáttur til að auka hafi verið kallaður út af skurðaðgerðir stofnfrumur að blóði fyrir safn og síðari samgena ígræðslu í sjúklingum við kirtlana og margar forráðamenn sem frumur að ná illa.

Plerixafor Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Ónæmisörvandi, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Almogran Filmuhúðuð tafla 12,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

almogran filmuhúðuð tafla 12,5 mg

almirall s.a.* - almotriptan d l-hýdrógen malat - filmuhúðuð tafla - 12,5 mg